Home Platform Pipeline Tools About Investors Contact Get in touch →
AI Drug Discovery & Cell Therapy

Off-the-Shelf
Cell Therapies
Without Immune Rejection.

AI drug discovery needs a human-cell validation foundation. Cell therapy needs HLA-matched allogeneic iPSCs. Wonderlab is the only company with a fully characterized iPSC platform covering 90%+ of the US population, providing the cells both fields require.

Investor Access → Our Platform →
$57M+
Platform Investment
85,000+
Fully Consented Donors
23
Patents
90%+
US Population Coverage
01 / 06
Three Areas
Where We Perform
A diversified platform.
A diversified platform spanning research tools, funded partnerships, and proprietary therapeutics.
01 . Tools

NAM Research Tools

iPSC-derived cells, mesenchymal stem cells, and cardiomyocytes for AI drug discovery validation, pharmaceutical screening, and non-animal model development.

02 . Partnerships

Non-Dilutive Research Partnerships

Competitively awarded federal research programs that advance our science and manufacturing capabilities alongside leading academic and government institutions.

03 . Therapeutics

Therapeutics Pipeline

Proprietary cell therapy and gene therapy programs targeting osteoarthritis, cardiac arrhythmia, and neurodegenerative disease.

02 / 06
The Cell Bank
Boston. Drydock Avenue.
The world's most comprehensive HLA-matched iPSC resource.

We built the first fully characterized HLA-matched allogeneic iPSC cell bank in the world, and it is still the largest one. The cells in it came from 85,000 consented donors. Among them are 65 HLA-homozygous super donors, the rare individuals whose immune signature is broad enough that their cells can be transplanted into more than nine of every ten Americans without being rejected.

With those cells in hand we can manufacture therapies in advance and have them ready when a patient needs them. The patient's body accepts the cells without immunosuppressive drugs, because the cells were matched to their immune type before they ever existed as a product. That is what we mean by off-the-shelf cell therapy.

Explore the Platform →
85,000+
Fully Consented Donors
65+
Super Donors Identified
>90%
US Population Coverage
100%
Reprogramming Success
8+
HLA Loci Typed
6
Differentiation Pathways
Inside the lab

A working bank
in Boston.

Behind these windows, in liquid nitrogen at minus 196 degrees, sit vials of cells from people who agreed to contribute. We reprogram those cells, characterize them across the immune markers that decide whether a transplant takes or fails, and bank them as a resource for the cell therapies still to come. The work happens in Boston, every day.

Boston . Manufactured in-house
03 / 06
Where AI Drug
Discovery Meets
Human Biology
The validation foundation.
AI drug discovery needs a human-cell validation foundation. Cell therapy needs HLA-matched allogeneic iPSCs. Wonderlab provides the cells both fields require, a fully characterized, population-scale iPSC platform covering 90% of the US population.
PREDICT

AI Drug Discovery

Computational models can propose thousands of candidate molecules a day. Human biology cannot test them at that speed.

→
VALIDATE

Wonderlab iPSCs

65+ HLA-matched super donors, fully characterized and differentiable into any cell type.

Plus 85,000+ consented samples for AI validation across real human populations.

→
TRANSLATE

Off-the-Shelf Therapies

The cells used to test a candidate molecule are the same cells we manufacture the therapy from.

The Category Differentiator

Wonderlab's 65+ super donors were identified from a screen of 85,000+ consented samples, the population-scale donor pool that powers the platform. For AI drug discovery, that breadth is the differentiator: candidate validation against real human genetic diversity, not the handful of reference cell lines the field has relied on for decades.

04 / 06
Life Capsule
Collection
Where the donors come in.
Every donor in the platform started with a moment like this.
A decade of work.
Eighty-five thousand
fully consented donors.

The bank represents more than a decade of consented donor enrollment. Each of the 85,000 contributors went through a multi-stage informed-consent and screening process before any sample was retained. The result is a population-scale collection that would be difficult and expensive to assemble from scratch under current regulatory expectations.

Each line in the bank carries its provenance with it. Identity, consent scope, and the documented chain of custody travel with the cells through every stage of reprogramming, characterization, and storage. For research partners and regulators, that documented history is as much of an asset as the cells themselves.

85,000+
Donors enrolled
100%
Consented
65+
Super donor lines
05 / 06
Therapeutic
Pipeline
Multiple programs.
Multiple programs across four therapeutic areas, all from a single platform.
G3N-004
IND-Track
Knee Osteoarthritis
iPSC-Derived Chondrocytes
Injectable cell therapy to regenerate cartilage. Two completed animal studies with statistically significant repair.
G3N-008
Preclinical
Long QT Syndrome
iPSC-Derived Cardiomyocytes
iPSC-based disease modeling and gene editing platform for inherited cardiac arrhythmia. Orphan drug eligible.
G3N-012
In Development
Neurodegeneration
Neurons
iPSC-derived neuronal therapies targeting protein aggregation in Parkinson's disease and related conditions.
Full Pipeline Details →
Federally Funded Research

Areas of Focused Research

Our platform has been validated through use in competitively awarded, federally funded research programs.

Cartilage Regeneration
GMP-compatible manufacturing of iPSC-derived chondrocytes for joint repair.
Cells for Screening & Tools
iPSC-derived cell models for pharmaceutical drug discovery and non-animal testing.
Cardiac Therapeutics
iPSC-derived cardiomyocyte models for inherited arrhythmia and cardiac repair.
Neurology
Disease modeling and therapeutic development for neurodegenerative conditions.
[ 06 / 06 . Get in touch ]

Interested in
Wonderlab Bio?

We work with researchers, drug discovery teams, manufacturing partners, and investors who want to understand the platform in detail. The door is open.

Investor Access → Contact Us →